Dr Reddy Lab Q4 Results: Net Profit Rises 36% To Rs 1,307; Dividend Announce Rs 40 Sh

Hyderabad-based pharmaceutical company Dr. Reddy's Laboratories on Tuesday announced its financial results for the fourth quarter of the fiscal year 2023-24, with impressive growth across key metrics. The company reported a net profit of Rs 1,307 crore for the March quarter, marking a substantial 36% increase from the same period last year.

In the corresponding quarter of the previous year, Dr. Reddy's reported a net profit of Rs 960 crore. The company's revenue for the quarter stood at Rs 7,083 crore, up by 12% from the Rs 6,297 crore recorded in the year-ago quarter. Despite the challenging business environment, Dr. Reddy's has demonstrated resilience and continued to deliver strong financial results, supported by its diversified product portfolio and strategic initiatives.

The company recommended a final dividend of Rs. 40/- (800%) per equity share of Rs. 5/- each for the financial year 2023-24. The dividend will be paid on or after five days from the date of declaration of the final dividend by the shareholders at the ensuing 40th Annual General Meeting (AGM) of the company.

"The company has delivered healthy revenue growth during the quarter, aided by new product performance, an increase in the volume of base business in the US, new product launch momentum, and strong performance in Europe, partly offset by price erosion in the US and Europe." Prathamesh Masdekar, research analyst at StoxBox, said.

In a significant leadership transition, Mr. Parag Agarwal, the current Chief Financial Officer (CFO) of Dr. Reddy's, will retire effective from the close of working hours on July 31, 2024. Mr. M. V. Narasimham, currently the Deputy Chief Financial Officer (CFO) of the company, will succeed him as the CFO, effective August 1, 2024. This transition is part of the company's succession planning strategy and aims to ensure a smooth and seamless transfer of responsibilities.

"During the quarter, the company launched five new products in the US market. The company is focused on higher investments in sales and marketing activities to strengthen existing brands and new business initiatives, including scaling up OTC and consumer health and wellness businesses, digitalization initiatives, and building strong commercial capabilities," Prathamesh added.

Dr. Reddy's performance in the fourth quarter underscores its resilience and ability to navigate through challenging market conditions. The company remains focused on its strategic priorities, including expanding its product portfolio, enhancing operational efficiency, and driving innovation. With a strong financial performance and a robust growth outlook, Dr. Reddy's Laboratories is well-positioned to capitalise on emerging opportunities in the pharmaceutical sector and deliver sustainable value to its stakeholders.